Navigation Links
European Scientists Develop Novel Therapy for Cancer

A maximal therapy with minimal side effects - Scientists of a consortium led by the University of Crete Medical School,// Greece, has been awarded a grant from the European Commission Sixth Framework program for the discovery and validation of new therapeutic strategies for cancer.

The research program, code-named Apotherapy, will develop methods to activate a protein at the surface of ovarian, lung and bladder tumor cells which will stop their growth. This protein, called CD40, can also induce the destruction of malignant cells by the body's own defenses. The scientists who participate in the program aim to combine CD40 triggering with chemotherapy or with innovative drugs that will cut-off signals necessary for the survival of cancer cells. This strategy is expected to achieve maximal therapy with minimal side effects.

Dr Aristides Eliopoulos of the University of Crete Medical School who co-ordinates the Apotherapy research program, commented: "We are delighted to have received funding under this program grant. It gives us the opportunity to collaborate with some of the top European scientists and oncologists to fight this deadly disease. We are confident that in the near future, we will be able to progress the best of our developed strategies into clinical practice for the benefit of cancer sufferers."



Source-Eurekalert
SRI
'"/>




Page: 1

Related medicine news :

1. Lung Cancer Deaths Declining In Men But Not Women In European Countries
2. Record Growth Of Soya-Based Dairy Alternatives Over The Past Year In European Markets
3. European Countries To Fund $4 Billion For Vaccination For Poor Children’
4. Nanotechnology Revolution To Be Spearheaded By European Union
5. Detection of Weak strains of bird flu virus – Target of European Unio
6. Europe On High Bird Flu Alert: European Commission
7. Slovenia, Bulgaria, Greece Face Bird Flu Threat: European Union
8. Heart Brakes: Hearts in European Union Invite Health Attention
9. European Union: Poultry producers Need Aid to Survive Bird flu crisis
10. 5th European Breast Cancer Conference Talks about Everything from Patient to Oncologist
11. Control And Prevention Of Three Diseases To Be Discussed: European Commission
Post Your Comments:
(Date:7/25/2008)...alif., July 25 /PRNewswire/ -- AutoGenomics, Inc. ...tatement on Form S-1 with the,Securities and Excha...blic,offering of shares of its common stock. The n... of which are expected to be offered by,AutoGenomi...ve not yet been,determined., J.P. Morgan Securiti...
(Date:7/25/2008)... The Retina Group of New York will prese...cular degeneration especially designed for seniors...ic Library at 116 Merritts Road, Farmingdale, NY 1...ndance is free and refreshments will be provided. ...-6100. , Hicksville and H...
(Date:7/25/2008)... Columbus-based law firm represents Pick...ef purchased at Columbus-area Kroger store , ...uly 25, 2008 -- http://www.donaheyohioinjurylawye... personal injury law firms in central Ohio, has fi... Court (Case No. 08CV9804) against The Kroger Co.,...
(Date:7/24/2008)...inn., July 24 /PRNewswire-FirstCall/ -- ev3 Inc. (...port its 2008 second quarter and,year-to-date fina... quarter,and year-to-date financial results on Mon...ours., The company will host a conference call an...tern Time) on Tuesday, July 29, 2008. ev3,manageme...
Breaking Medicine News(10 mins):Health News:AutoGenomics, Inc. Files Registration Statement for Initial Public Offering 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 2Health News:Retina Group of New York To Present Seminar on Age-Related Macular Degeneration; The Leading Cause of Visual Loss in Seniors 3Health News:Donahey Law Firm Files E. Coli Product Liability Lawsuit Against Kroger Company in Franklin County Court 2Health News:ev3 Inc. Announces Revised Date for 2008 Second Quarter Financial Results and Conference Call 2
... the body from tissue damage also increases the ri...gton University School of Medicine in St. Louis te...thy cells // survive the effects of toxic chemothe... found that the protein encourages the growth of t...
...hwestern Medical Center have identified a step tha...a-amyloid that encourages the spread of the diseas...any other essential roles produces too much beta-a...he whole enzyme knocks out many of its other funct...
... and Molecular Biology (CCMB), Hyderabad has unrav... way for detecting the mechanisms that prevent can... Bhadra and Utpal Bhadra have been instrumental be...t a disease, which has remained a global challenge...
...i following the water borne diseases crossed 55 ev...mic. Most of the 55 dead were from the densely pop... last month's floods. Over 1,000 patients had been...with complications arising from leptospirosis, den...
Other Medicine News:Health News:Researchers Identified Process That Aids Spread Of Alzheimer’s’ Disea 2
(Date:7/23/2008)...Body Have Greater Concentrations of,Stem Cells, A...wire/ -- Fat removed,from the lower abdomen and in...xcellent source of stem cells, with higher stem ce...ports a Brazilian-based study in August,s,Plastic ...l journal of the,American Society of Plastic Surge...
(Date:7/23/2008)...all/ -- Dendreon Corporation,(Nasdaq: DNDN ) toda...onitoring Committee (IDMC) to review in October 20...ng to the Company,s Phase 3 IMPACT (IMmunotherapy,...as D9902B) clinical trial,of PROVENGE(R) (sipuleuc...ctive cellular immunotherapy for the treatment of ...
(Date:7/22/2008)...swire-FirstCall/ -- Following a,thorough review th...harmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) to...hase 3 study in liver cancer. Progen confirmed,its...olio of compounds and,the company will actively se...es through Merger & Acquisition activity., The st...
(Date:7/22/2008)...- Nonin Medical, a leading innovator,of physiologi...as entered,the clinical testing phase with its bre...turation. Today,s most common application for this...gional blood oxygenation,in the brain -- cerebral ...n ongoing clinical study at the,Duke University Me...
Breaking Medicine Technology:Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Is Tap Water Safe for Your Dog 3F 20799 1Is Tap Water Safe for Your Dog 3F 20799 2Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 1Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 2Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 3Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine 28R 29 28VNP40101M 29 and Cytarabine in Relapsed Acute Myelog 20797 4Mylan Inc Acquires Central Eastern European Generics Businesses of Merck KGaA 20795 1Mylan Inc Acquires Central Eastern European Generics Businesses of Merck KGaA 20795 2IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 1IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 2IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 3IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 4IDM Pharma Announces Data Supporting Improved Overall Survival Advantage in Newly Diagnosed Patients with Metastatic Osteosarcoma Treated with Mifamur 20793 5
...wire/ -- Results from,the primary analysis of a ra...owed that 77 percent of treatment-experienced HIV-...600 mg tablets with,100 mg ritonavir (PREZISTA/r) ...(OBR) of antiretroviral (ARV) agents, reached a,pl...ared to 68,percent of patients taking Kaletra(R)1 ...
...ire-FirstCall/ --,Genzyme Corp. announced top-line... studies to assess the safety and efficacy of,tole...polymer,therapy for patients with Clostridium diff... 3 study of tolevamer liquid is fully,enrolled and...irst Phase 3 study known as the Polymer Alternativ...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 2Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 3Genzyme Announces Data from First Phase 3 Study of Tolevamer in,Patients with C. difficile Associated Diarrhea 4
Only SurLok combines precise control, enhanced basket and grasper strength, and the added security of a unique wire-locking mechanism. You can feel the difference. The SurLok flat-wire and grasper ha
The SurLok helical stone baskets are constructed of strong and resilient stainless steel. These helical baskets present a spiral profile that effectively clears both stones and fragments.
The 3-way design permits continuous irrigation through a separate irrigation lumen in the Foley Catheter. 3-Way Catheters are available in Latex construction, as well as LUBRICATH coatings, and in a
The Coude tip design facilitates negotiation of the prostatic urethra. It is available in a medium length olive Coude tip with a single drainage eye. The red latex construction provides added stiffne
Medicine Products: